Table 4 Adverse events occurring in more than one patient in any treatment group up to 100 days post first transplantation
Comparison 1 | Comparison 2 | Comparison 3 | ||||
|---|---|---|---|---|---|---|
Adverse event, n (%) Standard organ class, n (%) | G-CSF + plerixafor (N = 77) | G-CSF alone (N = 41) | G-CSF + plerixafor (N = 129) | G-CSF + chemo (N = 129) | G-CSF + plerixafor + chemo (N = 117) | G-CSF + chemo (N = 117) |
Any adverse event up to 100 days post transplantation | 34 (44.2) | 20 (48.8) | 61 (47.3) | 55 (42.6) | 49 (41.9) | 50 (50.4) |
Infections and infestations | 30 (39.0) | 18 (43.9) | 51 (39.5) | 43 (33.3) | 38 (32.5) | 48 (41.0) |
Blood and lymphatic disorders | 2 (2.6) | 0 | 4 (3.1) | 6 (4.7) | 3 (2.6) | 7 (6.0) |
Gastrointestinal disorders | 2 (2.6) | 0 | 4 (3.1) | 1 (0.8) | 3 (2.6) | 3 (2.6) |
General disorders and administration site conditions | 10 (13.0) | 5 (12.2) | 17 (13.2) | 15 (11.6) | 13 (11.1) | 14 (12.0) |
Metabolism and nutritional disorders | N/A | N/A | 1 (0.8) | 3 (2.3) | 0 | 3 (2.6) |
Renal and urinary disorders | 0 | 1 (2.4) | 2 (1.6) | 0 | 0 | 1 (0.9) |
Nervous system disorders | 1 (1.3) | 2 (4.9) | 1 (0.8) | 1 (0.8) | 1 (0.9) | 1 (0.9) |
Cardiac disorders | 0 | 1 (2.4) | 1 (0.8) | 2 (1.6) | 1 (0.9) | 2 (1.7) |
Vascular disorders | 0 | 2 (4.9) | 1 (0.8) | 3 (2.3) | 3 (2.6) | 2 (1.7) |
